|
|
|
Context Therapeutics Inc (NASDAQ: CNTX) |
|
Context Therapeutics Inc
CNTX's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Context Therapeutics Inc 's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 4.43 %
Context Therapeutics Inc net loss increased from $-4 millions, to $-5 millions in first quarter of 2025,
• More on CNTX's Growth
|
|
Context Therapeutics Inc
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.69 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
• More on CNTX's Valuation
|
|
|
|
|
Context Therapeutics Inc
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 0.69 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.27.
Context Therapeutics Inc Price to Book Ratio is at 0.6 lower than Industry Avg. of 33.79. and higher than S&P 500 Avg. of 0.01
• More on CNTX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
